CurvaFix develops implantable products for repairing fractures in curved bones. Credit: Chinnapong / Shutterstock.com.

Medical device company CurvaFix has raised $39m in Series C financing to expand the treatment for patients with Fragility Fractures of the Pelvis (FFP) across the US.

Through the nationwide launch of the CurvaFix IM Implant, the company aims to fundamentally transform the care provided to these patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The financing round was led by MVM Partners and included participation from Sectoral Asset Management, along with other existing investors.

CurvaFix already secured 510(k) clearance from the US Food and Drug Administration for its CurvaFix IM Implant.

CurvaFix is mainly focused on the development of implantable products for repairing fractures in curved bones.

See Also:

MVM partner Eric Fritz said: “CurvaFix’s ability to benefit patients, physicians and health systems while simultaneously addressing the undertreated FFP segment, makes CurvaFix a rare asset in the crowded world of orthopaedics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are thrilled to be involved and look forward to supporting the company’s next phase of growth.”

Furthermore, CurvaFix has appointed Mark Foster as the company’s new CEO. He succeeded founder and current CEO Steve Dimmer, who will serve as strategic adviser.

Foster has experience in the medical device, pharmaceutical and healthcare industries, and is the former president and CEO of Trice Medical.

Foster said: “I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopaedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point.

“I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians and payers.”